New York – February 21, 2014 – Cooley LLP announced today that it advised the underwriters on Egalet Corporation's initial public offering. Egalet is a specialty pharmaceutical company that develops and plans to commercialize abuse-deterrent oral products. Egalet now trades on the NASDAQ Global Market under the symbol "EGLT."
Stifel, Nicolaus & Company, Incorporated and JMP Securities LLC acted as joint book-running managers for the offering. Canaccord Genuity and Janney Montgomery Scott acted as co-managers.
The Cooley corporate and securities team advising the underwriters was led by partners Bo Yaghmaie and Brent Siler, and included special counsel Brian Leaf, and associates Meredith Blount and Steve Bielecki. Critical support for the offering was provided by partner and chair of Cooley's health care & life sciences practice Drew Gantt, partner Natasha Leskovsek and associate David Sclar (regulatory); partner Carol Laherty and associate Michael Cooper (intellectual property); partner Ken Krisko and associate Christine Walchuk (life sciences) and partner Susan Cooper Philpot (tax).
This offering follows Cooley's record year in 2013 for capital markets in which the firm advised on 60 public offerings, including 23 IPOs, raising more than $8.4 billion. Year-to-date in 2014, Cooley has advised on 22 compelted public offerings, including 12 completed IPOs.
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.
Cooley has more than 750 lawyers across 11 offices in the United States and China.